Search research articles
Contact Us
Filters
Showing results (1-10 of 25) with videos related to
Page
of 3
Sort By:
Health Economics Review
|
December 3, 2016
Modelling the cost-effectiveness of human milk and breastfeeding in preterm infants in the United Kingdom
James Mahon, Lindsay Claxton, Hannah Wood
British Dental Journal
|
August 27, 2016
Author reply
Matthew Taylor, Lindsay Claxton, Liz Kay
BMJ (Clinical Research Ed.)
|
November 22, 2023
Cirrhosis in over 16s: assessment and management-updated summary of NICE guidance
Chris Carmona, Lindsay Claxton, Alastair O'Brien, et al.
Pharmacoeconomics
|
October 10, 2018
Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
Lindsay Claxton, Joanne O'Connor, Nerys Woolacott, et al.
Pharmacoeconomics
|
November 23, 2018
Correction to: Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
Lindsay Claxton, Joanne O'Connor, Nerys Woolacott, et al.
Drugs & Aging
|
October 11, 2014
Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK
Lindsay Claxton, Bill Malcolm, Matthew Taylor, et al.
Pharmacoeconomics
|
April 15, 2019
Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Matthew Walton, Sahar Sharif, Mark Simmonds, et al.
Pharmacoeconomics
|
October 28, 2016
Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom
Lindsay Claxton, Robert Hodgson, Matthew Taylor, et al.
Journal of Managed Care & Specialty Pharmacy
|
June 14, 2018
An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective
Lindsay Claxton, Matthew Taylor, Arif Soonasra, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 2, 2022
The Cost-Effectiveness of Selective Internal Radiation Therapies Compared With Sorafenib for Treating Advanced Unresectable Hepatocellular Carcinoma in the United Kingdom
Lindsay Claxton, Matthew Walton, Sahar Sharif-Hurst, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 25) with videos related to
Sort By:
Page
of 3
Health Economics Review
|
December 3, 2016
Modelling the cost-effectiveness of human milk and breastfeeding in preterm infants in the United Kingdom
James Mahon, Lindsay Claxton, Hannah Wood
British Dental Journal
|
August 27, 2016
Author reply
Matthew Taylor, Lindsay Claxton, Liz Kay
BMJ (Clinical Research Ed.)
|
November 22, 2023
Cirrhosis in over 16s: assessment and management-updated summary of NICE guidance
Chris Carmona, Lindsay Claxton, Alastair O'Brien, et al.
Pharmacoeconomics
|
October 10, 2018
Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
Lindsay Claxton, Joanne O'Connor, Nerys Woolacott, et al.
Pharmacoeconomics
|
November 23, 2018
Correction to: Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
Lindsay Claxton, Joanne O'Connor, Nerys Woolacott, et al.
Drugs & Aging
|
October 11, 2014
Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK
Lindsay Claxton, Bill Malcolm, Matthew Taylor, et al.
Pharmacoeconomics
|
April 15, 2019
Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Matthew Walton, Sahar Sharif, Mark Simmonds, et al.
Pharmacoeconomics
|
October 28, 2016
Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom
Lindsay Claxton, Robert Hodgson, Matthew Taylor, et al.
Journal of Managed Care & Specialty Pharmacy
|
June 14, 2018
An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective
Lindsay Claxton, Matthew Taylor, Arif Soonasra, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 2, 2022
The Cost-Effectiveness of Selective Internal Radiation Therapies Compared With Sorafenib for Treating Advanced Unresectable Hepatocellular Carcinoma in the United Kingdom
Lindsay Claxton, Matthew Walton, Sahar Sharif-Hurst, et al.
Page
of 3